Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SS)
CNY 88.82
(-1.03%)
CNY 88.82
(-1.03%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 695.32 Million CNY | 114.4% |
| 2022 | 324.3 Million CNY | 5.48% |
| 2021 | 307.46 Million CNY | 238.26% |
| 2020 | 90.89 Million CNY | 137.6% |
| 2019 | 38.25 Million CNY | 17.4% |
| 2018 | 32.58 Million CNY | -58.02% |
| 2017 | 77.62 Million CNY | 69.2% |
| 2016 | 45.87 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 936.96 Million CNY | 56.71% |
| 2024 Q1 | 597.9 Million CNY | -14.01% |
| 2023 Q4 | 695.32 Million CNY | 97.83% |
| 2023 FY | 695.32 Million CNY | 114.4% |
| 2023 Q2 | 308.55 Million CNY | -0.42% |
| 2023 Q1 | 309.86 Million CNY | -4.45% |
| 2023 Q3 | 351.48 Million CNY | 13.91% |
| 2022 Q3 | 324.07 Million CNY | -4.71% |
| 2022 Q1 | 288.36 Million CNY | -6.21% |
| 2022 FY | 324.3 Million CNY | 5.48% |
| 2022 Q4 | 324.3 Million CNY | 0.07% |
| 2022 Q2 | 340.1 Million CNY | 17.94% |
| 2021 Q2 | 137.07 Million CNY | 108.17% |
| 2021 FY | 307.46 Million CNY | 238.26% |
| 2021 Q1 | 65.84 Million CNY | -27.56% |
| 2021 Q4 | 307.46 Million CNY | 43.95% |
| 2021 Q3 | 213.58 Million CNY | 55.81% |
| 2020 FY | 90.89 Million CNY | 137.6% |
| 2020 Q4 | 90.89 Million CNY | 103.46% |
| 2020 Q3 | 44.67 Million CNY | 10.51% |
| 2020 Q2 | 40.42 Million CNY | 38.45% |
| 2020 Q1 | 29.19 Million CNY | -23.67% |
| 2019 FY | 38.25 Million CNY | 17.4% |
| 2019 Q2 | 44.3 Million CNY | 0.0% |
| 2019 Q3 | 38.93 Million CNY | -12.11% |
| 2019 Q4 | 38.25 Million CNY | -1.74% |
| 2019 Q1 | - CNY | -100.0% |
| 2018 FY | 32.58 Million CNY | -58.02% |
| 2018 Q4 | 32.58 Million CNY | 0.0% |
| 2017 FY | 77.62 Million CNY | 69.2% |
| 2016 FY | 45.87 Million CNY | 0.0% |